Foster Dykema Cabot & Partners’s AstraZeneca AZN Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155K	Hold	820	–	–	0.01%	129
2026 Q1	$162K	Sell	820 -1	-0.1%	-$193	0.01%	127
2025 Q4	$151K	Hold	821	–	–	0.01%	136
2025 Q3	$126K	Hold	821	–	–	0.01%	156
2025 Q2	$115K	Hold	821	–	–	0.01%	158
2025 Q1	$121K	Hold	821	–	–	0.01%	150
2024 Q4	$108K	Sell	821 -5	-0.6%	-$700	0.01%	168
2024 Q3	$129K	Buy	826 +178	+27%	+$28.7K	0.01%	159
2024 Q2	$101K	Hold	648	–	–	0.01%	144
2024 Q1	$87.7K	Hold	648	–	–	0.01%	151
2023 Q4	$87.2K	Buy	+648	New	+$84.2K	0.01%	136

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Foster Dykema Cabot & Partners's AZN Position: Q2 2026 in Review

Foster Dykema Cabot & Partners held its AstraZeneca (AZN) position steady in Q2 2026 at 820 shares worth $155K. The position accounts for 0.01% of the portfolio, ranked #129.

Foster Dykema Cabot & Partners first reported a position in AZN in Q4 2023 and has held it in 11 quarters since. The position peaked at $162K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Foster Dykema Cabot & Partners held 820 shares of AstraZeneca worth $155K as of Q2 2026.
Foster Dykema Cabot & Partners left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #129 holding.
Foster Dykema Cabot & Partners first reported a position in AstraZeneca in Q4 2023 and has held it in 11 quarters since.
Foster Dykema Cabot & Partners's AstraZeneca position peaked at $162K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.